Skip to main content
OFIX
NASDAQ Industrial Applications And Services

Orthofix Lowers 2026 Guidance, Withdraws Long-Term Targets Due to Medicare Reimbursement Cuts

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$12.07
Mkt Cap
$491.123M
52W Low
$10.24
52W High
$16.99
52W Position info
18% above low
Off High info
29% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

OFIX sits 18% above its 52-week low of $10.24.

Summary

Orthofix Medical Inc. has lowered its full-year 2026 financial guidance and withdrawn its long-term targets due to an expected 10% decline in Medicare reimbursement rates for its bone growth stimulators.


Key Events · Earnings and Guidance · OFIX

  • Medicare Reimbursement Cut

    CMS updated billing requirements for non-invasive bone growth stimulators, leading to an expected 10% decline in average Medicare reimbursement for HCPCS codes E0747, E0748, and E0760, effective May 18, 2026.

  • Lowered 2026 Financial Outlook

    The company now expects full-year 2026 net sales in the range of $838 million to $848 million and non-GAAP adjusted EBITDA between $90 million and $93 million, a reduction from previous expectations.

  • No Positive Free Cash Flow Expected

    Orthofix Medical Inc. does not anticipate achieving positive free cash flow for the full-year 2026, exacerbating cash concerns previously noted in the Q1 2026 10-Q.

  • Three-Year Targets Withdrawn

    The company's previously issued three-year financial targets are no longer applicable due to these developments, signaling increased long-term uncertainty.


Analysis · OFIX · Industrial Applications And Services

Orthofix Medical Inc. has significantly revised its financial outlook for 2026 and withdrawn its three-year financial targets. This follows a U.S. Food and Drug Administration reclassification of non-invasive bone growth stimulators and subsequent Centers for Medicare & Medicaid Services (CMS) updates, which are expected to reduce average Medicare reimbursement for these devices by approximately 10%. The lowered guidance for net sales and adjusted EBITDA, coupled with the expectation of no positive free cash flow for the full year, indicates a material negative impact on the company's profitability and liquidity, introducing considerable uncertainty for investors.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OFIX was trading at $12.07 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $491.1M. The 52-week trading range was $10.24 to $16.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OFIX - Latest Insights

OFIX
Nov 12, 2026, 6:08 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $7.01
Real-time Price: $6.52 info
Change: -$0.490 (-7%) info
Market Cap: $265.754M info
OFIX
Nov 12, 2026, 5:39 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $6.94
Real-time Price: $6.52 info
Change: -$0.420 (-6%) info
Market Cap: $265.754M info
OFIX
Nov 09, 2026, 8:02 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.65
Real-time Price: $6.52 info
Change: -$0.130 (-2%) info
Market Cap: $265.754M info
OFIX
Nov 09, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.65
Real-time Price: $6.52 info
Change: -$0.130 (-2%) info
Market Cap: $265.754M info
OFIX
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.09
Real-time Price: $6.52 info
Change: -$0.5707 (-8%) info
Market Cap: $265.754M info